Alvogen Initiates Class I Recall of Fentanyl Transdermal System Due to Defective Delivery System
Alvogen, Inc. has initiated a Class I recall (D-0245-2025) for 112,128 cartons of Fentanyl Transdermal System CII, 25mcg/h, due to a defective delivery system. Patches manufactured by Kindeva Drug Delivery L/P may be multi-stacked in pouches, posing a severe patient safety risk. This nationwide recall demands immediate attention from procurement and regulatory teams to manage supply chain disruptions for this critical opioid.
FDA Class I Recall: Defective Fentanyl Transdermal System Poses Severe Patient Risk
Alvogen, Inc. has initiated a Class I recall, identified as D-0245-2025, for its Fentanyl Transdermal System CII, 25mcg/h. This critical action, initiated on January 31, 2025, stems from a defective delivery system where patches could be multi-stacked or adhered one on top of the other within a single product pouch. The FDA's Class I classification signifies that use of or exposure to this product carries a reasonable probability of causing serious adverse health consequences or death, a direct and severe implication for patient safety and healthcare providers. The recall impacts a substantial quantity of 112,128 cartons, each containing five pouches, distributed nationwide across the USA. For procurement directors, this represents an immediate and significant disruption to the supply of a Schedule II controlled substance essential for pain management. Regulatory affairs heads must recognize the heightened scrutiny from the FDA on Alvogen and its manufacturing partner, Kindeva Drug Delivery L/P, given the severe risk profile. Business development executives should assess the potential for market shifts and the need for robust quality control in similar transdermal drug delivery systems.
Manufacturing Origin and Product Scope for Recalled Fentanyl System
The recalled Fentanyl Transdermal System CII, 25mcg/h, distributed by Alvogen, Inc. from its Morristown, NJ, address, was manufactured by Kindeva Drug Delivery L/P, located in Northridge, CA 91324. This distinction is crucial for supply chain VPs, highlighting the reliance on contract manufacturing organizations (CMOs) for critical drug products. The specific product involved is identified by NDC 47781-424-47, with an application number ANDA202097, and comes from Lot #: 108319, carrying an expiration date of April 30, 2027. Fentanyl, classified as a full opioid agonist, is a potent analgesic used in chronic pain management, making its consistent and safe delivery paramount. The nationwide distribution pattern means that healthcare systems and pharmacies across the entire USA are affected by this recall. Procurement teams must understand the manufacturing origin to evaluate their due diligence processes for CMOs, especially for high-risk products like controlled substances. Regulatory affairs professionals should note that the responsibility for product quality ultimately rests with the marketing authorization holder, Alvogen, even when manufacturing is outsourced, necessitating stringent quality agreements and oversight with Kindeva Drug Delivery L/P.
Commercial Impact and Supply Chain Resilience for Controlled Substances
The recall of 112,128 cartons of Alvogen's Fentanyl Transdermal System CII, 25mcg/h, distributed nationwide, creates a significant commercial impact and immediate supply chain challenge for a vital Schedule II controlled substance. Procurement directors must urgently assess existing inventory levels and potential shortages within their networks, as the defective delivery system could lead to underdosing or overdosing if multiple patches are inadvertently applied or if a single pouch contains fewer than expected. This situation underscores the critical need for robust supply chain resilience, particularly for drugs with high abuse potential and strict regulatory controls. The absence of readily available alternative suppliers in the current intelligence landscape means that procurement teams face a constrained market for this specific dosage form and delivery method. Business development executives should recognize the potential for reputational damage to both Alvogen and Kindeva Drug Delivery L/P, which can influence future partnerships and market positioning. Supply chain VPs must prioritize contingency planning, exploring expedited qualification processes for any potential alternative sources, and enhancing inbound quality checks for all high-risk pharmaceutical products to prevent similar disruptions.
Regulatory Outlook and Remediation Expectations for Alvogen and Kindeva
The FDA's classification of this event as an ongoing Class I recall signals a high level of regulatory concern and mandates a comprehensive response from Alvogen, Inc. and its manufacturer, Kindeva Drug Delivery L/P. As a voluntary firm-initiated recall, Alvogen is expected to conduct a thorough root cause analysis to identify precisely why the Fentanyl Transdermal System patches were multi-stacked or adhered within pouches. Regulatory affairs heads must ensure that Alvogen implements robust corrective and preventive actions (CAPA) to address the manufacturing defect, which will be subject to stringent FDA review. This includes potential modifications to manufacturing processes, quality control checks, and packaging lines at Kindeva's Northridge facility. The ongoing status of the recall indicates that the FDA will closely monitor the effectiveness of these remediation efforts. Failure to adequately address the underlying issues could lead to further enforcement actions, including potential Warning Letters or import alerts if the product were sourced internationally, impacting Alvogen's future product approvals and market access. Procurement directors should track the resolution timeline closely, as it will directly influence the long-term stability of Fentanyl Transdermal System supply and Alvogen's standing as a reliable supplier.